Muscarinic acetylcholine signalling plays major roles in regulation of consciousness, cognitive functioning, pain perception and circulatory homeostasis. Halothane has been shown to inhibit m1 muscarinic signalling. However, no comparative data are available for desflurane, sevoflurane or isoflurane, nor have the anaesthetic effects on the m3 subtype (which is also prominent in the brain) been studied. Therefore, we have investigated the effects of these compounds on isolated m1 and m3 muscarinic receptor function. Defolliculated Xenopus oocytes expressing recombinant m1 or m3 muscarinic or (for comparison) AT 1A angiotensin II receptors were voltage clamped, and Ca 2; -activated Cl . A similar, although not significant, trend was observed with m3 signalling. Isoflurane had no effect on m1 signalling, but profoundly inhibited m3 signalling. Sevoflurane depressed the function of m1 and m3 signalling in a dosedependent manner. Halothane, similar to its known effect on m1 signalling, dose-dependently depressed m3 function. I Cl(Ca) induced by intracellular injections of IP 3 were unaffected by all four anaesthetics. Similarly, none of the anaesthetics tested affected AT 1A signalling. Absence of interference with AT 1A signalling and intracellular pathways suggest that the effects of anaesthetics on muscarinic signalling most likely result from interactions with the m1 or m3 receptor molecule. Multiple interaction sites with different affinities may explain the biphasic response to desflurane. Anaesthetic-specific effects on closely related receptor subtypes suggest defined sites of action for volatile anaesthetics on the receptor protein.
Muscarinic acetylcholine signalling plays major roles in regulation of consciousness, cognitive functioning, pain perception and circulatory homeostasis. Halothane has been shown to inhibit m1 muscarinic signalling. However, no comparative data are available for desflurane, sevoflurane or isoflurane, nor have the anaesthetic effects on the m3 subtype (which is also prominent in the brain) been studied. Therefore, we have investigated the effects of these compounds on isolated m1 and m3 muscarinic receptor function. Defolliculated Xenopus oocytes expressing recombinant m1 or m3 muscarinic or (for comparison) AT 1A angiotensin II receptors were voltage clamped, and Ca 2; -activated Cl currents (I Cl(Ca) ) induced by acetyl-␤-methylcholine (Mch) or angiotensin II were measured in the presence of clinically relevant concentrations of halothane, sevoflurane, desflurane or isoflurane. To determine the site of action of the volatile anaesthetics we compared anaesthetic effects on m1, m3 and AT 1A receptor function and studied the effects of volatile anaesthetics on signalling induced by intracellular injection of the second messenger IP 3 . Desflurane had a biphasic effect on m1 signalling, enhancing at a concentration of 0.46 mmol litre 91 but depressing at 0.92 mmol litre
91
. A similar, although not significant, trend was observed with m3 signalling. Isoflurane had no effect on m1 signalling, but profoundly inhibited m3 signalling. Sevoflurane depressed the function of m1 and m3 signalling in a dosedependent manner. Halothane, similar to its known effect on m1 signalling, dose-dependently depressed m3 function. I Cl(Ca) induced by intracellular injections of IP 3 were unaffected by all four anaesthetics. Similarly, none of the anaesthetics tested affected AT 1A signalling. Absence of interference with AT 1A signalling and intracellular pathways suggest that the effects of anaesthetics on muscarinic signalling most likely result from interactions with the m1 or m3 receptor molecule. Multiple interaction sites with different affinities may explain the biphasic response to desflurane. Anaesthetic-specific effects on closely related receptor subtypes suggest defined sites of action for volatile anaesthetics on the receptor protein.
(Br. J. Anaesth. 1998; 81: 569-577).
Keywords: theories of anaesthetic action, molecular; anaesthetics volatile; receptors, muscarinic In addition to the well known actions in circulatory and respiratory regulation, 1 2 muscarinic acetylcholine signalling plays an important role in the central nervous system (CNS). Level of consciousness is modulated significantly by brainstem muscarinic signalling. 3 Cholinergic antagonists affect memory and learning abilities through actions on the basal forebrain, cortex and hippocampus. 4 5 Spinal muscarinic receptors mediate antinociception, predominantly in the substantia gelatinosa of the dorsal horn, and also affect motor neurone areas. 6 7 Anaesthetics cause CNS depression and alter bronchial tone and heart rate, effects which may be mediated in part by interactions with muscarinic signalling. 8 9 Various anaesthetics are known to alter ligand binding to muscarinic receptors. Ether, 10 halothane, 11 chloroform, enflurane and isoflurane 12 were shown to increase muscarinic antagonist binding. However, these initial reports investigated mixed receptor populations and did not study receptor activation. More refined methods of investigating anaesthetic mechanisms became available when the members of the muscarinic receptor subfamily were cloned. Hence the influence of anaesthetics on the function of individual receptor subtypes can now be studied. Recently, we reported that halothane 13 and ketamine 14 inhibited m1 muscarinic signalling. This study was designed to extend the initial findings with halothane. First, we wished to investigate if the effect of halothane on muscarinic signalling was subtype-specific. Therefore, we studied anaesthetic actions on the m3 muscarinic receptor, which is also expressed widely in brain. 15 16 Second, we wished to investigate if the effects of halothane could be extrapolated to other volatile anaesthetics. Thus we studied the muscarinic inhibitory effects of sevoflurane, isoflurane and desflurane. The comparison between isoflurane and desflurane was of specific interest, as these anaesthetics are closely related structurally: desflurane differs from isoflurane only in the substitution of fluorine for chlorine on the ␣-ethyl carbon. However, in contrast with isoflurane, desflurane has been noted to induce a relative sympathetic activation, resulting in significantly increased heart rate and mean arterial pressure compared with isoflurane.
We hypothesized that this effect might result in part from muscarinic inhibition, and that, despite their structural similarities, these anaesthetics might show divergent effects on muscarinic receptor function.
Therefore, we have determined the action of desflurane, isoflurane and sevoflurane on m1 and m3 muscarinic and, as a comparison, on angiotensin II receptor function. In addition, the effects of halothane on m3 signalling were investigated. Specifically, we investigated if the anaesthetics, at clinically comparable concentrations, influenced m1 and m3 muscarinic signalling, and where in the signalling pathway their effects were localized. The rat m1 and m3 muscarinic acetylcholine receptors were a gift from T. I. Bonner (National Institutes of Mental Health, Bethesda, MD, USA). Its complementary DNA (cDNA) consists of a 2.8-kilobasepair (kpb) fragment in a commercial vector (pGEM1; Promega, Madison, WI, USA). The construct for m1 expression was linearized by digestion with the nuclease HindIII, and complementary RNA (cRNA) was transcribed in vitro using the bacteriophage RNA polymerase T7. A capping analogue ( 7m GpppG) was included in the reaction to generate capped transcripts, as these are translated more efficiently in the oocyte. The resulting cRNA was quantified by spectroscopy and diluted in water to a concentration of 0.1 mg ml
Materials and methods

XENOPUS
91
. Oocytes were each injected with 5 ng of cRNA using an automated microinjector (Nanoject; Drummond Scientific, Broomall, PA, USA). Adequacy of injection was confirmed by noting the slight increase in cell size during injection. m3 muscarinic cDNA was subcloned in the pCMV vector. cDNA 10 ng in H 2 O 9.5 nl was injected directly into the germinal vesicle (nucleus) of the oocyte. This technique bypasses in vitro cRNA preparation and therefore yields faster and more convenient, although less reliable, expression. activated Cl 9 current (I Cl(Ca) ), integrated and expressed as micro coulombs (C), is a measure of intracellular Ca 2; release. [20] [21] [22] [23] The upward deflection during agonist application at times observed in the traces is a slight motion artefact. All experiments were performed at room temperature (approximately 22ЊC).
Microelectrodes were pulled in one stage from capillary glass (BBL with fibre; World Precision Instruments, Sarasota, FL, USA) on a micropipette puller (model 700C; David Kopf Instruments, Tujunga, CA, USA). Tips were broken to a diameter of approximately 10 m, providing a resistance of 1-3 MΩ, and filled with KCl 3 mol litre
. A single oocyte was placed in a perfusable bath containing 3 ml of Tyrode's solution containing (mmol litre 91 ): NaCl 150, KCl 5, MgCl 2 1, CaCl 2 2, glucose 10, HEPES 10, pH adjusted to 7.4 with NaOH. Two microelectrodes were inserted into the oocyte, and a holding potential of 970 mV was applied to the membrane. The voltage clamp amplifier (OC725A; Warner Corporation, New Haven, CT, USA) was connected to a data acquisition and analysis system running on an IBM-compatible personal computer. The acquisition system consisted of a DAS-8 A/D conversion board (Keithly-Metrabyte, Taunton, MA) and analysis was performed with OoClamp software. 24 Occasional cells that did not show a stable holding current of less than 1 A during a 1-min equilibration period were excluded from analysis.
Membrane -release better than peak current. 25 Any motion artefact on agonist delivery was excluded from analysis. Each oocyte received a single agonist application only. ) was microinjected using the same nanoinjector mentioned above. IP 3 , when injected into the cell, induces an I Cl(Ca) similar to that observed after receptor activation in the oocyte. IP 3 -induced I Cl(Ca) was evoked by injecting 50 nl of IP 3 2 mmol litre 91 in water into the oocyte. Each oocyte was injected only once with IP 3 ; therefore, any kinetic effects observed were not caused by time-dependent effects or run-down after multiple injections. Control injections with water as vehicle were performed to assure a specific action of IP 3 .
STATISTICAL ANALYSIS
Results are reported as mean (SEM). As variability between batches of oocytes is common, responses were at times normalized to same-day controls for each batch. Differences between treatment groups were analysed using ANOVA and Student's unpaired t test, appropriately corrected for multiple comparisons (Bonferroni). P:0.05 was considered significant. Concentration-response curves were fit to the following logistic function, derived from the Hill equation:
where y max and y min :maximum and minimum response obtained, respectively, n:the Hill coefficient, and x 50 :concentration at which the half-maximal response occurs (EC 50 for agonist, IC 50 for anaesthetics). In figure 1D , curve fitting was performed on averaged raw data. In the other graphs, because of variability of oocyte batches from different frogs, data were normalized to the same day control value and then the fitting was performed on the averaged normalized values. All fitting values are given in were delivered using agent-specific vaporizers (carrier gas:air at 500 ml min
91
) and equilibrated in Tyrode's solution by bubbling for at least 10 min. Oocytes were exposed to anaesthetics for approximately 5 min before testing. Bath concentrations of anaesthetics were verified by gas chromatography (Aerograph 940, Varian Analytical Instruments, Walnut Creek, CA, USA) using saline-gas partition coefficients (P sol/gas ) at 22ЊC for isoflurane (1.08), sevoflurane (0.52), halothane (1.20) and desflurane (0.45) (estimations for desflurane and sevoflurane were based on the observation that P sol/gas is approximately twice as great at 22ЊC as at 37ЊC). fig. 1D . Currents developed within several seconds after agonist application, and returned to baseline after approximately 30 s. Average response sizes were 3.4 (0.8) C for the m1 receptor, 5.0 (1.2) C for the m3 receptor and 1.6 (0.6) C for the AT 1A receptor. These findings are similar to those reported in our previous studies, where we showed that these currents were I Cl(Ca) . 13 14 To ensure that the responses were mediated by specific receptors, we attempted to inhibit them with antagonists. Atropine (fig. 1B) In contrast with desflurane, isoflurane had no effect on Mch-induced m1 muscarinic signalling ( fig. 3A) . At very high concentrations (0.75-0.96 mmol litre 91 ) an inhibitory trend was noted ( fig. 3B ). However, these effects were not statistically significant. The effects of isoflurane on m1 signalling were therefore different from those of desflurane, especially when the actions of the two compounds were compared at MAC-equivalent concentrations. In contrast with its lack of effect on m1 signalling, isoflurane inhibited m3 signalling (IC 50 0.45 mmol litre 91 ) ( fig. 3C ).
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Results
FUNCTIONAL EXPRESSION OF MUSCARINIC AND ANGIOTENSIN RECEPTORS IN XENOPUS
1 mol litre 91 completely inhibited responses to Mch in oocytes expressing m1 and m3 receptors
SEVOFLURANE AND HALOTHANE INHIBITED M1 AND M3
SIGNALLING
Sevoflurane and halothane inhibited m1 and m3 muscarinic signalling. We have reported previously that halothane inhibits m1 signalling with an IC 50 of 0.3 mmol litre
91
. 13 In this study, we found that it inhibited m3 signalling with an IC 50 of 0.88 mmol litre 91 ( fig. 4C ). Sevoflurane inhibited m1 and m3 signalling in a similar manner (IC 50 0.32 mmol litre 91 for m1 muscarinic inhibition ( fig. 4A ) and 0.75 mmol litre 91 for m3 muscarinic signalling ( fig. 4B) ). Thus, the m1 receptor appeared to display higher sensitivity to the inhibitory effects of halothane and sevoflurane.
ANGIOTENSIN II AND MUSCARINIC RECEPTORS SHARED THE SAME INTRACELLULAR SIGNALLING PATHWAY
As we wished to study the effects of the anaesthetics on angiotensin signalling to localize their site of action, it was necessary to demonstrate that angiotensin and muscarinic receptors signal through the same pathway. We have shown previously that AT 1A receptors expressed in Xenopus oocytes signal through the IP 3 pathway, as signalling can be blocked specifically by intracellular microinjection of the IP 3 receptor antagonist heparin. 29 To confirm the experiments reported previously, and to determine if muscarinic signalling uses the same pathway, we evaluated the effect on signalling of microinjection of 
heparin (2 ng nl
91
, 60 nl, 30 min before recording) into oocytes expressing m1 or AT 1A receptors. m1 muscarinic signalling was inhibited to the same degree as angiotensin signalling ( fig. 5A ). Heparin microinjection into the oocyte inhibited responses to Mch by 93% compared with controls ( fig. 5B ). In contrast, microinjected water had no effect on either muscarinic or angiotensin signalling (data not shown). As the oocyte expresses only a single isoform of phospholipase C, coupling receptor activation to intracellular Ca 2; release, 21 our findings indicate that the muscarinic and AT 1A signalling pathways are identical downstream of the G protein (compare fig. 1A ).
SITE OF ACTION: VOLATILE ANAESTHETICS HAD NO EFFECT ON ANGIOTENSIN SIGNALLING
As muscarinic and angiotensin signalling use the same intracellular second messenger pathways, we investigated the effect of desflurane, isoflurane and sevoflurane on AT 1A receptor function. In contrast with their variable effects on m1 and m3 signalling, the anaesthetics used had no effect on AT 1A signalling, even at high concentrations ( fig. 5C ). Similar results were reported for halothane. 13 These results indicate that the actions of these anaesthetics on m1 and m3 signalling are not mediated by effects on the intracellular pathways, as these are shared by muscarinic and angiotensin receptors.
SITE OF ACTION: VOLATILE ANAESTHETICS HAD NO EFFECT
ON IP 3 -INDUCED CL 9 
CURRENTS
To elucidate further the site of action of volatile anaesthetics on muscarinic signalling, we determined the effect of the anaesthetics on currents induced by microinjected IP 3 (50 nl of 2 mmol litre
91
, yielding approximately 100 mol litre 91 intracellularly). IP 3 -induced Cl 9 currents resembled the responses induced by receptor activation (fig. 6A ). In contrast, microinjected water was ineffective ( fig. 6B) . Desflurane, even at high concentrations, had no effect on IP 3 -induced currents, indicating that this agent affects the signalling pathway before interaction between IP 3 and its receptor ( fig. 6B ). Similarly, we have shown that halothane, isoflurane and sevoflurane have no effect on intracellular IP 3 signalling or signalling induced by direct G-protein activation with GTP␥S.
REVERSIBILITY OF ANAESTHETIC ACTION
To complete this investigation, we determined the reversibility of anaesthetic inhibition of muscarinic signalling. Data are presented in figure 7 . In all cases, anaesthetic inhibition was reversible on wash-out.
Discussion
Muscarinic signalling by m1 and m3 receptors was inhibited in a differential manner by the volatile anaesthetics studied. Halothane and sevoflurane, in clinically relevant concentrations, inhibited muscarinic signalling, with the m1 receptor displaying a higher sensitivity than the m3 receptor. Isoflurane had no effect on m1 muscarinic signalling, even at concentrations which would be anticipated to disrupt membrane structure, 28 but significantly inhibited m3 signalling. Desflurane showed a biphasic effect on both receptors.
Differences in effect between desflurane and isoflurane are remarkable, as the two compounds differ only in a single halogen atom: a chlorine atom in isoflurane is replaced by a fluorine atom in desflurane. Thus minor changes in chemical structure can induce significant pharmacological effects.
The biphasic action of desflurane on muscarinic signalling is unusual, although not unprecedented. Ryanodine 31 and adenosine 32 are known to act similarly in various models. Our study was not designed to determine the molecular mechanism of this biphasic action. However, we could rule out interactions with the intracellular signalling pathway, as none of the anaesthetics had effects on both AT and IP 3 signalling. Hence the site of action is most likely at the muscarinic receptor or (possibly) the associated G protein. Biphasic responses are explained most easily by the existence of two different binding sites at the receptor with different affinities and different agonistic-antagonistic effects when occupied. Mutagenesis studies may be able to delineate such various binding sites on the muscarinic receptor.
Our findings should be interpreted in view of the artificial environment in which the receptors were expressed. However, muscarinic and angiotensin receptors have been expressed frequently in the Xenopus oocyte model system, both by ourselves 13 14 and others, 33 34 and it is well established that they function similarly in oocytes as they do in native cells. Although the receptors are expressed at a lower temperature than they are normally exposed to, this has not been shown to result in significant changes in kinetics or function.
Any attempt to correlate our findings to observed clinical effects of anaesthetics is arduous, as conclusions drawn from several receptor subtypes cannot be transferred to a complex organism and its response to anaesthesia. Although most clinical and experimental data comparing isoflurane and desflurane show a congruence in their CNS 35 36 and circulatory effects, [37] [38] [39] some unexplained differences exist. Desflurane is known to exhibit less negative inotropic activity and to induce smaller decreases in arterial pressure. 39 When heart rate, mean arterial pressure and sympathetic nerve activity were compared after 10.9% desflurane anaesthesia 2 min after induction in humans, all variables were enhanced significantly compared with isoflurane 17 ; after more prolonged anaesthesia there were no differences between the anaesthetics. This initial period of excitation, when anaesthetic concentrations are relatively low, could result potentially from interactions with muscarinic signalling pathways. It would be of great interest to study the interactions between desflurane and adrenergic receptor functioning, as excitatory effects of desflurane directly on the ␤-adrenergic receptor or on presynaptic ganglia might also explain its excitatory effects. CNS muscarinic stimulation raises the level of consciousness and improves learning. 3 It is interesting to speculate if stimulation of m1 signalling (the most prominent cerebral muscarinic subtype) by low desflurane concentrations might contribute to the rapid mental recovery observed with the anaesthetic. 40 If so, this might be of particular importance in elderly patients with limited CNS muscarinic signalling reserve (e.g. patients with Alzheimer's disease). The prominence of the m3 subtype in bronchial smooth muscle 41 and glands 1 could explain in part the irritating effect of desflurane during induction and emergence from anaesthesia, when anaesthetic concentrations are relatively low.
In brief, we have demonstrated that desflurane had a concentration-dependent biphasic effect on m1 and m3 muscarinic receptor functioning, whereas isoflurane had no effect on m1 signalling but pronounced effects on m3 signalling. We have also shown that halothane and sevoflurane inhibited m1 and m3 signalling in a dose-dependent manner. This action is most likely localized at the receptor level, as the anaesthetics did not influence intracellular signalling pathways. In addition, the anaesthetics had no effect on angiotensin signalling. In combination with our findings that halothane inhibits m1 signalling in a concentration-dependent manner, 13 these results show that different volatile anaesthetics affect m1 and m3 muscarinic signalling in highly divergent ways, and that small changes in chemical structure of the volatile anaesthetic or the receptor can significantly affect anaesthetic-protein interactions.
